AXLA

In a report released today, Thomas Smith from SVB Securities maintained a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $6.00. The company's shares closed last Tuesday at $2.03. According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -24.9% and a 22.8% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Eledon Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $9.50 average price target, a 370.3% upside from current levels.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-axcella-health-axla?utm_source=advfn.com&utm_medium=referral